PROCEPT BioRobotics Corporation (PRCT)
Nasdaq · Healthcare · Medical Devices
$17.82+3.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.0B
- 52-week range
- $16.67 – $38.11
- 52-week change
- −51.31%
- EPS (trailing)
- −$1.94
- Analyst rating
- 2.6 Hold
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $308M (+37.22%)
- Net income
- −$96K
- Operating margin
- −33.7%
- Diluted EPS
- −$1.72
- Free cash flow
- −$58.3M
From the company’s annual report on SEC EDGAR.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Headquarters: San Jose, United States · 888 employees · procept-biorobotics.com